dr. sherman comments on cabozantinib and vandetanib in medullary thyroid cancer
Published 11 years ago • 746 plays • Length 2:41Download video MP4
Download video MP3
Similar videos
-
1:34
dr. eric sherman on the sequencing of cabozantinib and vandetanib for mtc
-
1:29
dr. sherman discusses the vandetanib trial
-
55:43
cabozantinib for radioiodine-refractory differentiated thyroid cancer with dr. sherman
-
4:42
treatment-related toxicity in advanced medullary thyroid cancer
-
1:54
dr. eric sherman discusses vandetanib's dosage and precautions
-
2:20
dr. sherman on pazopanib in anaplastic thyroid cancer
-
1:56
dr. brose on vandetanib for differentiated thyroid cancer
-
1:31
dr. langmuir on vandetanib in medullary thyroid cancer
-
5:17
utilizing tkis for advanced medullary thyroid cancer
-
8:05
genetic testing and screening in medullary thyroid cancer
-
7:50
targeted therapeutic advances in advanced medullary thyroid cancer
-
1:09:19
medullary thyroid cancer: ask a doctor your questions. dr. sherman. thyca conference
-
1:47
dr. sherman on the relationship between thyroid-stimulating hormone levels and outcomes from select
-
0:43
cabozantinib's targeting potential
-
4:40
vandetanib for progressive and symptomatic medullary thyroid cancer
-
1:00:23
medullary thyroid cancer targeted therapy with dr zafereo 163
-
5:59
multidisciplinary treatment of medullary thyroid cancer
-
1:11
dr. manisha shah on cabozantinib impact on tumor shrinkage in differentiated thyroid cancer
-
7:02
using cabozantinib to treat medullary thyroid cancer—expert video 4 of 5